Skye Bioscience, Inc. (SKYE)
USD 1.4
(-2.1%)
USD 1.4
(-2.1%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 13.54 Million USD | 11.9% |
| 2022 | 12.1 Million USD | 54.27% |
| 2021 | 7.84 Million USD | 24.78% |
| 2020 | 6.28 Million USD | -5.18% |
| 2019 | 6.63 Million USD | 41.34% |
| 2018 | 4.69 Million USD | 21.59% |
| 2017 | 3.85 Million USD | -13.67% |
| 2016 | 4.47 Million USD | 3.55% |
| 2015 | 4.31 Million USD | 58.04% |
| 2014 | 2.73 Million USD | 2168.76% |
| 2013 | 120.4 Thousand USD | 1678.48% |
| 2012 | 6770.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.15 Million USD | 51.61% |
| 2024 Q2 | 8.4 Million USD | 36.63% |
| 2023 Q2 | 2.99 Million USD | -3.4% |
| 2023 Q1 | 3.1 Million USD | 0.73% |
| 2023 Q4 | 4.05 Million USD | 16.25% |
| 2023 FY | 13.54 Million USD | 11.9% |
| 2023 Q3 | 3.49 Million USD | 16.55% |
| 2022 Q4 | 3.07 Million USD | 5.32% |
| 2022 Q1 | 2.88 Million USD | 17.32% |
| 2022 Q2 | 3.21 Million USD | 11.44% |
| 2022 Q3 | 2.92 Million USD | -9.2% |
| 2022 FY | 12.1 Million USD | 54.27% |
| 2021 Q3 | 1.81 Million USD | -0.58% |
| 2021 Q4 | 2.46 Million USD | 35.32% |
| 2021 Q2 | 1.82 Million USD | 5.32% |
| 2021 Q1 | 1.73 Million USD | 31.72% |
| 2021 FY | 7.84 Million USD | 24.78% |
| 2020 FY | 6.28 Million USD | -5.18% |
| 2020 Q3 | 1.53 Million USD | 26.02% |
| 2020 Q2 | 1.22 Million USD | -44.8% |
| 2020 Q4 | 1.31 Million USD | -14.26% |
| 2020 Q1 | 2.21 Million USD | 19.95% |
| 2019 Q3 | 1.5 Million USD | -15.12% |
| 2019 FY | 6.63 Million USD | 41.34% |
| 2019 Q2 | 1.77 Million USD | 16.89% |
| 2019 Q4 | 1.84 Million USD | 22.65% |
| 2019 Q1 | 1.51 Million USD | 15.18% |
| 2018 FY | 4.69 Million USD | 21.59% |
| 2018 Q4 | 1.31 Million USD | 25.8% |
| 2018 Q3 | 1.04 Million USD | -3.2% |
| 2018 Q2 | 1.08 Million USD | -13.68% |
| 2018 Q1 | 1.25 Million USD | 26.85% |
| 2017 FY | 3.85 Million USD | -13.67% |
| 2017 Q4 | 986.51 Thousand USD | 29.53% |
| 2017 Q1 | 1.38 Million USD | 51.32% |
| 2017 Q2 | 730.92 Thousand USD | -47.04% |
| 2017 Q3 | 761.63 Thousand USD | 4.2% |
| 2016 Q2 | 1.48 Million USD | 21.44% |
| 2016 FY | 4.47 Million USD | 3.55% |
| 2016 Q3 | 856.14 Thousand USD | -42.23% |
| 2016 Q4 | 912.05 Thousand USD | 6.53% |
| 2016 Q1 | 1.22 Million USD | 5.71% |
| 2015 FY | 4.31 Million USD | 58.04% |
| 2015 Q3 | 896.29 Thousand USD | -33.93% |
| 2015 Q4 | 1.15 Million USD | 28.8% |
| 2015 Q2 | 1.35 Million USD | 49.1% |
| 2015 Q1 | 909.82 Thousand USD | -46.51% |
| 2014 Q4 | 1.7 Million USD | 98.34% |
| 2014 Q3 | 857.61 Thousand USD | 1700.65% |
| 2014 Q2 | 47.62 Thousand USD | -24.0% |
| 2014 Q1 | 62.66 Thousand USD | 42.01% |
| 2014 FY | 2.73 Million USD | 2168.76% |
| 2013 Q1 | 61.73 Thousand USD | 59.33% |
| 2013 Q2 | 58.53 Thousand USD | -5.18% |
| 2013 Q3 | 56.82 Thousand USD | -2.93% |
| 2013 Q4 | 44.12 Thousand USD | -22.34% |
| 2013 FY | 120.4 Thousand USD | 1678.48% |
| 2012 FY | 6770.00 USD | 0.0% |
| 2012 Q1 | 550.00 USD | 0.0% |
| 2012 Q2 | 93.00 USD | -83.09% |
| 2012 Q3 | 6127.00 USD | 6488.17% |
| 2012 Q4 | 38.74 Thousand USD | 532.33% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -914.47% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -168.692% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 54.158% |
| Nascent Biotech, Inc. | 2.22 Million USD | -507.546% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1940.294% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 63.636% |
| Qrons Inc. | 643.67 Thousand USD | -2004.712% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -3377.601% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 76.414% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -3160.706% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 84.39% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -175.474% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -5076.234% |
| SQZ Biotechnologies Company | 85.61 Million USD | 84.177% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -364.556% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -802.028% |
| Mesoblast Limited | 5.9 Million USD | -129.542% |
| Marizyme, Inc. | 19.23 Million USD | 29.586% |
| Genus plc | 147.7 Million USD | 90.828% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -54.314% |
| Pharming Group N.V. | 225.49 Million USD | 93.992% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -561.274% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -909.847% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -62.46% |
| ContraFect Corporation | 56.88 Million USD | 76.186% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -207.293% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -816.148% |
| IMV Inc. | 37.7 Million USD | 64.074% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -385.513% |
| MultiCell Technologies, Inc. | 567.42 USD | -2387470.054% |
| ONE Bio Corp. | 6.44 Million USD | -110.239% |
| Accustem Sciences Inc. | 3.74 Million USD | -261.613% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 84.237% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -2446.714% |
| Q BioMed Inc. | 3.43 Million USD | -294.211% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 45.185% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -415.602% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1262.683% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 86.361% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -669.888% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -101.66% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -626.656% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 54290.2% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 15.382% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -638.248% |
| GB Sciences, Inc. | 1.42 Million USD | -853.711% |
| Alpha Cognition Inc. | 9.7 Million USD | -39.585% |
| HST Global, Inc. | 140.9 Thousand USD | -9514.533% |
| CSL Limited | 3.44 Billion USD | 99.607% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1104.323% |
| Halberd Corporation | 74.84 Thousand USD | -18001.534% |
| Enzolytics Inc. | 2.17 Million USD | -521.588% |
| Agentix Corp. | 1.37 Million USD | -887.606% |
| Resverlogix Corp. | 12.71 Million USD | -6.573% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -271.094% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.117% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1197.658% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -463.323% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -757.79% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -297.875% |
| AVAX Technologies, Inc. | 7.31 Million USD | -85.322% |
| Zenith Capital Corp. | 8.94 Million USD | -51.488% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.359% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -77665.628% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -451.764% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -7799.032% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -605.269% |
| Kadimastem Ltd | 2.41 Million USD | -462.113% |
| Helix BioMedix, Inc. | 1.97 Million USD | -586.984% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -24.667% |
| BioStem Technologies, Inc. | 22.97 Million USD | 41.033% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -7364.832% |
| LadRx Corporation | 3.81 Million USD | -255.412% |
| Cell Source, Inc. | 4.32 Million USD | -213.213% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1366.963% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1366.963% |
| NovAccess Global Inc. | 2.46 Million USD | -449.204% |
| Affymax, Inc. | 39.38 Million USD | 65.603% |
| Itoco Inc. | 919.14 Thousand USD | -1373.933% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -219.637% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1110.684% |
| Mobile Lads Corp. | 554.54 Thousand USD | -2342.998% |
| CytoDyn Inc. | 18.05 Million USD | 24.978% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -53726.334% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -6055.795% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -854.193% |
| SYBLEU INC | 160.87 Thousand USD | -8321.113% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -645.879% |
| International Stem Cell Corporation | 5.27 Million USD | -157.02% |
| Bioxytran, Inc. | 3.82 Million USD | -254.634% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -25635.249% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -66495.635% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 62.644% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -737.302% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1741.112% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -335.473% |
| Neutra Corp. | 243.82 Thousand USD | -5456.351% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 22.395% |
| PureTech Health plc | 144.59 Million USD | 90.631% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 33.882% |
| IXICO plc | 4.7 Million USD | -187.817% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -54.002% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 88.494% |
| CSL Limited | 3.89 Billion USD | 99.652% |
| Cellectis S.A. | 97.32 Million USD | 86.079% |